Off-target binding or vector sequestration can significantly limit the efficiency of systemic virotherapy. We report here that systemically administered oncolytic measles virus (MV) was rapidly sequestered by the mononuclear phagocytic system (MPS) of the liver and spleen in measles receptor CD46-positive and CD46-negative mice. Since scavenger receptors on Kupffer cells are responsible for the elimination of blood-borne pathogens, we investigated here if MV uptake was mediated by scavenger receptors on Kupffer cells. Pretreatment of cells with poly(I), a scavenger receptor ligand, reduced MV expression by 99% in murine (J774A.1) macrophages and by 50% in human (THP-1) macrophages. Pre-dosing of mice with poly(I) reduced MPS sequestration of MV and increased circulating levels of MV by 4 to 15-folds at 2 min post virus administration. Circulating virus was still detectable 30 min post infusion in mice pre-dosed with poly(I) whereas no detectable MV was found at 5-10 min post infusion if mice did not receive poly(I). MPS blockade by poly(I) enhanced virus delivery to human ovarian SKOV3ip.1 and myeloma KAS6/1 xenografts in mice. Higher gene expression and improved control of tumor growth was noted early post therapy. Based on these results, incorporation of MPS blockade into MV treatment regimens is warranted.
Introduction
Tumor-selective oncolytic viruses, which have multiple mechanisms of antitumor activity and target diverse pathways in the malignant cell, represent an exciting new class of targeted therapeutics for cancer therapy. Viruses can cause direct cell destruction and/or elicit innate and cellular antitumor immune responses that result in control of distant metastases. [1] [2] [3] Based on promising phase II data, two oncolytic viruses, OncoVexGMCSF and Reolysin, are in phase III clinical testing, either as a single agent or in combination with standard chemotherapy in melanoma or head and neck cancer. 4, 5 Although oncolytic viruses hold much promise, there are several challenges associated with systemic virotherapy for the treatment of metastatic or surgically inaccessible tumors. 6 Intravenously administrated viruses can quickly be inactivated by neutralizing antibodies in virus immune patients. 7, 8 Strategies that help viruses evade antibodies include coating viral particles with polyethylene glycol or polymers, hiding the virus in cell carriers or serotype switching. [8] [9] [10] [11] [12] Viral particles can also be opsonized and sequestered by the reticuloendothelial system, resulting in shorter circulatory half-lives and reduced bioavailability to tumor cells. [13] [14] [15] To minimize sequestration, strategies that deplete serum factors such as complement or Factor X (using cobra venom factor or warfarin), macrophages (using clodronate liposomes or adenoviral particles) or blockade of scavenger receptors (using polyinosinoic acid) have been attempted. [16] [17] [18] [19] Finally, the viral particles need to extravasate efficiently from the tumor blood vessels into the tumor parenchyma to initiate an infection. Indeed these are generic issues that apply to systemic administration of most viruses and various groups are developing innovative approaches to overcome these challenges. [20] [21] [22] [23] We and others have been developing the attenuated Edmonston B lineage of measles virus (MV) as a tumorselective oncolytic agent for cancer therapy. 24 Two recombinant MVs modified to enable non-invasive monitoring, MV-CEA and MV-NIS, are currently undergoing clinical testing in patients with ovarian cancer, multiple myeloma or glioblastoma. [25] [26] [27] [28] [29] [30] Oncolytic MV infects cells by binding to one of two MV receptors, CD46 or SLAM (signaling lymphocyte activation molecule). The virus is highly fusogenic; infected cells fuse with their neighbors to form multinucleated syncytia, thereby facilitating viral spread through the infected culture. 31 The virus has shown promising antitumor activity in numerous mouse xenograft models of human malignancies, including lymphoma, multiple myeloma, ovarian, colorectal, breast, prostate, liver cancer and glioma. 6, 29, 30, [32] [33] [34] [35] [36] [37] Tumor selectivity of MV is in part due to high CD46 receptor density on the tumor cell surface, resulting in more extensive cytopathic effects compared with non-transformed cells. 29, 38, 39 For example, CD138-positive primary multiple myeloma cells express significantly higher levels of CD46 receptors per cell (49 130 molecules) than CD138-negative non-myeloma cells from the bone marrow (7340 molecules). 40 Potent cytopathic effects of extensive intercellular fusion were observed in measles-infected primary myeloma cells and not in the non-myeloma cells. 40 Despite numerous studies evaluating the antitumor potency of MV, the in vivo fate of systemically administered oncolytic MV particles has not been reported before. In this study, we investigated the biodistribution of MV particles in two murine models; non-transgenic, CD46-negative mice and CD46-positive transgenic mice. CD46-negative athymic or severe combined immunodeficiency mice are used routinely in efficacy studies for evaluation of the antitumor activity of MV against human tumor xenografts. As all non-transformed human cells except erythrocytes express CD46 at low levels, we have also used transgenic mice, which express the human CD46 receptor with a human-like distribution and level of expression in this study. These CD46 transgenic mice have been extensively used in MV pathogenesis studies and in toxicology/pharmacology studies in support of Investigational New Drug applications to the Food and Drug Administration to test MV in phase I clinical trials. In the current study, we demonstrated that intravenously administered MV was rapidly sequestrated by macrophages in the liver and spleen of mice, and that sequestration was independent of CD46 expression, and was mediated by virus binding to scavenger receptors on murine macrophages. Scavenger receptors form a large family of receptors (class A to H) that recognize negatively charged or opsonized materials and are responsible for the clearance of ligands in vivo, including DNA, damaged erythrocytes and endotoxin. 15, 41 Analysis of murine tissues has shown that most macrophage populations express scavenger receptor A, which is found most abundantly on Kupffer cells, alveolar macrophages and lamina propria macrophages in the gut. 42 Ligands such as polyinosinic acid (poly(I)), a synthetic single-stranded RNA can bind to scavenger receptor A to competitively inhibit uptake of viruses, bacteria or oxidized erythrocytes by macrophages. 18, [42] [43] [44] It appears that the base-quartetstabilized four-stranded helix of poly(I) is a necessary structural determinant for binding to and inhibition of scavenger receptors. The negatively charged phosphates in polynucleotide quadruplexes may form a charged surface that is complementary to the positively charged surface of the collagenous ligand-binding domain of the scavenger receptor. 45 Previous studies have shown that pre-administration of poly(I) before phage or adenovirus infusion decreased macrophage sequestration of the viral particles. 18, 46, 47 In this study, pre-dosing mice with poly(I) was performed to evaluate the impact of macrophage blockade on the circulatory half-life and antitumor activity of MV in two models of human cancer, multiple myeloma and ovarian cancer.
Materials and methods

Cells and viruses
The murine macrophage cell line J774A.1 (ATCC, TIB-67) and the human monocyte cell line THP-1 (American Type Culture Collection (ATCC), TIB-202) were obtained from ATCC (Manassas, VA). J774A.1 was cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and THP-1 was cultured in RPMI-1640 plus 10% fetal bovine serum and 0.05 mM b-mercaptoethanol. Phorbol-12-myristate-13-acetate, 100 nM, was added to the culture media to differentiate THP-1 monocytes into macrophages. The human epithelial ovarian carcinoma, SKOV3ip.1, was maintained in a-minimum essential medium supplemented with 20% fetal bovine serum and 2 nM L-glutamine. The human multiple myeloma cell line, KAS6/1, was cultured in 10% fetal bovine serum RPMI-1640 medium supplemented with 1 ng ml À1 recombinant human interleukin-6 (R&D Systems, Minneapolis, MN).
Recombinant Edmonston strain MV expressing firefly luciferase (MV-Luc) and or the thyroidal sodium iodide symporter (MV-NIS) were propagated as previously described. 26, 28 Viral titers were determined by 50% tissue culture infective dose (TCID 50 ) (median tissue culture infective dose) plaque-forming assay on Vero cells. 48 Fluorescent DiI or DiO-labeled MV particles were generated by adding Vybrant cell-labeling solution (Invitrogen, Carlsbad, CA) during virus propagation as previously described. 49 In vitro infection and reporter-gene expression analysis Murine macrophages (J774A.1), human monocytes (THP-1) and human macrophages (phorbol-12-myristate-13-acetate-treated THP-1) were seeded into 24-well culture plates at a density of 10 5 cells per well. After 24 h, cells were incubated for 1 h at 37 1C in the presence or absence of poly(I) or polyadenylic acid (poly(A)) (SigmaAldrich, St Louis, MO). After 1 h, MV-Luc was added (MOI ¼ 0.5). Two hours after infection, the infection medium was replaced by standard growth medium and cells were incubated for 48 h before assay for luciferase gene expression. For the luciferase assay, cells were lyzed with cell-culture lysis buffer (Promega, Madison, WI) and the lysates were analyzed with the luciferase assay system (Promega) on a LumiCount luminometer (Packard, Meriden, CT). All data are expressed as relative light units.
Mice
All animal experiments were approved by and performed according to guidelines of the Institute Animal Care and Use Committee of the Mayo Foundation. Because murine tissues do not express MV receptors and hence cannot be infected by the virus, we have used two murine models in this study; the CD46 transgenic (CD46 þ ) mouse, IfnarCD46Ge, which expresses the human CD46 receptor with the same tissue specificity 50 and CD46 receptor-negative (CD46À) immunocompromised athymic or severe combined immunodeficiency mice in which human tumor xenografts can be established. Ifnar-CD46Ge mice were bred in-house. Female athymic mice or ICR-severe combined immunodeficiency mice were purchased from Harlan (Indianapolis, IN) or Taconic (Germantown, NY), respectively.
The effect of poly(I) on mononuclear phagocytic system (MPS) sequestration of MV was studied using athymic (CD46 negative) and Ifnar-CD46Ge (CD46 positive) mice. Mice were injected with phosphatebuffered saline (PBS) or PBS containing 0.2 mg poly(I) per mouse 5 min before injection of 10 6 TCID 50 fluorescently labeled MV-Luc through either the tail vein (athymic) or orbital plexus (Ifnar-CD46Ge). As the CD46-positive mice have a black tail, which makes intravenous (i.v.) administration technically challenging, we have opted to administer the virus by the orbital plexus. Biodistribution studies on viral genomes have indicated comparable viral distribution by IV administration via the tail vein and retro-orbital (Peng, unpublished) . Liver and spleen were harvested 3 h after injection, snap frozen in optimal cutting temperature and 5 mm cryosections were photographed under fluorescence microscopy. Fluorescent MV-Luc-positive cells were quantitated using Image J software (NIH, Bethesda, MD). MV blood circulation times were determined by collecting an aliquot of blood via the retro-orbital plexus at 2, 5, 10 and 30 min after virus administration. Plasma was obtained and the amount of MV particles was determined by TCID 50 assay on Vero cells.
For studying the effect of poly(I) on delivery of MV particles to the tumor site, athymic mice bearing subcutaneous SKOV3ip.1 tumors were given 0.2 mg poly(I) 5 min before 10 6 TCID 50 MV-Luc was injected intravenously through the tail vein. For studying the effect of poly(I) on tumor growth, athymic mice bearing subcutaneous SKOV3ip.1 tumors and ICR-severe combined immunodeficiency mice bearing subcutaneous KAS6/1 tumors were given 0.2 mg poly(I) i.v. 5 min before i.v. administration of MV-NIS (10 7 TCID 50 for SKOV3ip.1 tumors and 10 5 TCID 50 for KS6/1 tumors).
Immunohistochemistry
Liver and spleen tissues from athymic mice and IfnarCD46Ge mice were frozen in optimal cutting temperature medium and 5 mm cryosections were cut onto slides. The tissues were fixed in acetone (À20 1C) for 10 min and permeabilized using 0.01% Triton-X in PBS for 15 min. Blocking buffer containing 5% horse serum in PBS was applied for 20 min, and after which tissues were incubated with rat anti-murine CD68 antibody (Abcam, Cambridge, MA) for 1 h at room temperature. Slides were washed five times in PBS, and followed by incubation with Alexa 488-conjugated anti-rat antibody (Abcam) for 30 min.
Quantitative reverse transcriptase-PCR for measles nucleoprotein mRNA Tissues from MV-NIS-injected mice were harvested 4 h after virus injection and frozen in RNAlater solution (Ambion, Austin, TX). Total RNA was extracted from 10 to 20 mg of tissue, using RNeasy plus mini kits (Qiagen, Valencia, CA). Co-isolated DNA was removed by spinning through the gDNA Eliminator spin columns (Qiagen). A 61-base product of the MV-N gene was amplified using the iScript One-Step RT-PCR kit (Bio-Rad, Hercules, CA) as previously described. 51 Statistical analysis Statistical significance of experimental results was analyzed by unpaired Student's t-test where indicated. A P value of o0.05 is considered statistically different.
Results
Systemically administered MV particles are sequestered by the MPS of the liver and spleen
We have used two murine models in this study, CD46-negative athymic mice and Ifnar-CD46Ge mice genetically modified to express the human CD46 receptor with the same tissue specificity as in humans. 50, 52 Use of both models allows us to evaluate the impact of CD46 expression on the biodistribution of MV particles. At 2, 5, 10 and 30 min post i.v. injection of MV in mice, blood samples were collected and the amount of infectious virus in the serum was analyzed by virus titration (TCID 50 ) assay. There was a rapid decline in the amount of infectious MV from the circulation of both CD46-negative and CD46-positive mice (Figure 1) . The half-life of circulating MV was about 1 min.
To determine if disappearance of infectious virus was due to neutralization by murine blood, MV was added exogenously into whole blood harvested from athymic mice and Ifnar-CD46Ge mice or media (Opti-MEM, Invitrogen, Carlsbad, CA) and incubated for 30 min at 37 1C. Plasma was separated from whole blood on a Ficoll gradient and the amount of infectious virus was quantitated by TCID 50 titration on Vero cells. As shown in Table 1 , about 10% of input virus was found associated with lymphocytes from the CD46-positive mice. However, the majority (63-84%) of the input virus remained infectious in the plasma/platelets fraction even after 30 min of mixing at 37 1C ( Table 1 ), suggesting that the rapid disappearance of infectious MV from the circulation was not due to virus inactivation by mouse blood.
To facilitate in vivo tracking of viral particles, MV was labeled fluorescently with either DiI or DiO lipophilic dyes and injected i.v. into mice. To ensure all circulating viruses have arrived at their destination, the mice were harvested at 3 h post MV infusion. Major organs were examined under blue light to determine which tissues have taken up the DiO green fluorescently labeled MV. Both the liver and spleen were strongly positive for green fluorescent cells. Further analysis of the liver and spleen cryosections confirmed the presence of abundant green fluorescent cells in both CD46-negative athymic and CD46-positive transgenic mice (Figure 2a) . Green fluorescent cells were uniformly distributed in the liver parenchyma whereas the spleen showed a more distinct circular pattern around the white pulp. 53 To determine if the cells that had phagocytosed MV were macrophages, colocalization studies were performed using immunohistochemical staining for CD68, a macrophage marker. Red fluorescent cells in the liver and spleen, which had taken up the DiI-labeled red fluorescent MV colocalized with CD68-positive cells, identifying macrophages as the cells responsible for uptake of Dil-MV (Figure 2b) .
To more accurately measure the relative levels of MV uptake by the respective organs, quantitative reverse transcriptase-PCR for MV-nucleocapsid mRNA was performed. Very high amounts of viral particles were found in the liver (3 Â 10 5 copies per mg total RNA) and spleen (1.5 Â 10 5 copies per mg total RNA) of CD46-positive mice (Figure 2c ). In contrast to the athymic mice, a significantly higher amount of MV (6 Â 10 5 copies per mg total RNA) was also found in the lungs of IfnarCD46Ge mice (Po0.05). Lower amounts of MV genomes were also detected in the kidneys and brains of IfnarCD46Ge mice, likely as a result of MV interaction with CD46 on these tissues. 52 In CD46-negative athymic mice, viral particles were found mainly in the liver (3 Â 10 5 copies per mg total RNA) and spleen (8 Â 10 4 copies per mg total RNA). Taken together, these data indicate that a significant portion of systemically administered MV can be taken up by cells of the MPS of the liver and spleen independent of CD46 expression.
Scavenger receptors are involved in MV particles uptake in macrophages
The rapid clearance of MV from the circulation and sequestration into the liver and spleen is likely a result of virus binding to scavenger receptors on macrophages. To evaluate the role of scavenger receptors in MV uptake, macrophages were pretreated with synthetic singlestranded RNA, poly(I) or poly(A). Poly(I) is a broadspecificity scavenger receptor inhibitor whereas poly(A) inhibits a more limited subset of scavenger receptors. 15 In particular, poly(I) is able to bind scavenger receptor class A whereas poly(A) does not. 15 Human monocyte (THP-1), human macrophage (THP-1 treated with phorbol-12-myristate-13-acetate) and murine macrophage (J774A.1) cell lines were pre-incubated with poly(I) or poly(A) before infection with MV encoding the firefly luciferase gene (MV-Luc). In the absence of poly(I) or poly(A), MV-Luc was able to infect and express in J774A.1 cells (B10 4 relative light units) even though murine macrophages do not express the measles CD46 receptor (Figure 3) , although the level of luciferase activity in J774.1 cells was 10 times lower than in CD46-positive human THP-1 macrophages (data not shown). Addition of poly(I) significantly (Po0.05) inhibited luciferase gene expression levels in all three cell types (Figure 3) . In J774A.1 cells, the (Figures 4b and c) .
Inhibition of the scavenger receptors enhanced MV delivery to the tumor and retarded tumor growth To determine if the reduced sequestration by MPS and prolonged circulation times impacted delivery of MV to the tumor site, MV-Luc was administered systemically into athymic mice bearing SKOV3ip.1. tumors after the mice had been pre-dosed with poly(I) or saline. Bioluminescent imaging data indicated that there was no detectable luciferase signal in the subcutaneous SKOV3ip.1 tumors in mice given MV-Luc alone (Figures 5a and b) . In contrast, all three mice given poly(I) and MV-Luc showed robust luciferase signal in the SKOV3ip.1 tumors by day 5 and luciferase gene expression remained strong at day 10. These data suggest that pre-dosing with poly(I) enhanced MV delivery to the tumor site allowing the virus to initiate a sustained infection.
The impact of poly(I) on the antitumor activity of MV-NIS, a recombinant MV currently undergoing clinical testing in patients with ovarian cancer and myeloma, was assessed in two established tumor xenograft models, subcutaneous SKOV3ip1 ovarian (Figure 5c ) and KAS6/1 myeloma (Figure 5d ) tumors. Mice were randomized into three treatment groups and received one dose of saline, saline/MV-NIS or poly(I)/MV-NIS. As shown in Figures  5c and d , there was no significant difference in the tumor volumes between mice given saline or a subtherapeutic dose of MV-NIS. In contrast, pre-dosing with poly(I) resulted in a significant inhibition of tumor growth compared with the saline controls in both tumor models (Po0.05). As the mice were given only a single subtherapeutic dose of virus, the tumors continued to grow in the treated animals and the Kaplan-Meier survival curves were not significantly enhanced compared with the saline control.
Discussion
Numerous studies have demonstrated the antitumor activity of MV in human tumor xenografts established in mice but there have been no published reports on the fate of intravenously administered MV particles in research animals. Here, we demonstrated that a 30 min exposure of MV to murine blood at 37 1C did not result in significant reduction in viral infectivity and the majority (63-84%) of the input virus remained infectious in the plasma/platelets fraction. Upon systemic administration in mice, MV particles have a short circulating half-life of about 1 min due to rapid uptake of particles by macrophages in the liver and spleen. Quantitative reverse transcriptase-PCR for viral mRNA confirmed that the amounts of virus trapped in the liver and spleen were comparable in both CD46-positive transgenic mice and CD46-negative athymic mice, demonstrating that sequestration of MV by the MPS was not due to CD46. Immunohistochemical staining of the liver and spleen cryosections from athymic and Ifnar-CD46Ge mice indicated that MV particles were taken up by macrophages. Blocking scavenger receptors with a competitive ligand poly(I) in vitro on macrophage cell lines or in vivo in mice significantly reduced MV uptake by macrophages.
In the liver, specialized macrophages (Kupffer cells) are predominantly distributed on the lumenal surface of hepatic sinusoids and have an important role in removing potentially harmful materials and particulate matter such as bacterial endotoxins, microorganisms, immunecomplexes and tumor cells from the blood. Several viruses such as vesicular stomatitis virus, simian immunodeficiency virus and adenoviruses were also found to be efficiently cleared from the circulation by Kupffer cells. 13, 14, 54 Recently, a number of studies demonstrated that adenoviruses can use scavenger receptor A as a direct route to enter Kupffer cells. 15, 47, 55 Administration of poly(I) into mice before adenovirus injection significantly reduced the capacity of Kupffer cells to trap adenoviral particles, although the impact of poly(I) pre-dosing on antitumor activity of the adenoviral vector was not evaluated in that study. Here, we confirmed that MV is able to bind to scavenger receptors on macrophage cells and this route of entry was inhibited more than 99% by poly(I) and poly(A) on the murine macrophage J774.1 cell line. Interestingly, addition of poly(I) but not poly(A) also inhibited 50% of MV gene expression in CD46 receptorpositive human THP-1 macrophage cell line, indicating the scavenger receptor (or other receptors blocked by poly(I)) can mediate uptake of MV by human macrophages.
Pre-dosing of athymic mice and Ifnar-CD46Ge mice with poly(I) prolonged the circulatory half-life of MV, resulting in a 15-fold and 4-fold increase, respectively, of MV levels in the blood early post virus infusion. Though modest, this increase in MV circulating half-life had an impact on virus delivery to tumors, enhancing virus delivery to and infection of tumor xenografts. Importantly, poly(I) pre-dosing resulted in superior tumor control by MV-NIS in two different models of human malignancy (ovarian and myeloma), at least at the early time points post delivery. As the aim of the experiment was to evaluate the impact of poly(I) on MV delivery, tumor-bearing mice were given only one dose of MV-NIS and the survival curves of mice treated with or without poly(I) were not significantly different at the end of the experiment. Nonetheless, this single delivery of MV at subtherapeutic levels clearly demonstrated the advantage of incorporating poly(I) in the treatment regimen to increase the bioavailability of the systemically applied virus.
The safety and feasibility of using poly(I) as a potential pre-dosing agent before virotherapy in cancer patients remains to be evaluated. It is important to point out that poly(I) is a single-stranded RNA and is less effective at inducing interferon-a in leukocytes compared with double-stranded small RNA polyI:C. 56 Systemic administration of poly(I) at 0.2 mg per mouse induced no observable toxicity in livers of athymic mice although transient higher serum levels of interleukin-6, MCP-1 and tumor necrosis factor-a were detected. 55 Alternative ligands of scavenger receptor A could be tested in lieu of poly(I) if clinical testing is desired, for example, fucoidan 44, 57 or using an alternative strategy to transiently eliminate macrophages using clodronate loaded liposomes. 58 Although polyI:C has been given as a adjuvant in vaccination protocols in human studies 59 and fucoidan has been given orally to humans, 60, 61 intravenous administration of poly(I), fucoidan or clodronate liposomes in humans has not been reported. Intravenous use of these agents will require testing in toxicology studies to evaluate feasibility for clinical use. Instead of blocking or saturating the MPS using ligands, one could employ other strategies such as shielding the viral vectors with polymers such as polyethylene glycol or HPMA copolymers to minimize vector recognition and uptake by the MPS. 62, 63 Tumor-homing cells have also been used as carriers to deliver oncolytic viruses to tumor xenografts 64 and also protect the viruses from inactivation by serum factors such as complement and antiviral antibodies. 10 The relative effectiveness of these different strategies at increasing the bioavailability of viruses and their applicability in clinical practice remains to be compared in future studies.
